Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aromatase inhibitors in breast cancer.
Smith IE, Dowsett M. Smith IE, et al. N Engl J Med. 2003 Jun 12;348(24):2431-42. doi: 10.1056/NEJMra023246. N Engl J Med. 2003. PMID: 12802030 Review. No abstract available.
Circulating tumour cells in breast cancer.
Ring A, Smith IE, Dowsett M. Ring A, et al. Among authors: smith ie. Lancet Oncol. 2004 Feb;5(2):79-88. doi: 10.1016/S1470-2045(04)01381-6. Lancet Oncol. 2004. PMID: 14761811 Review.
Efficacy and safety of trastuzumab.
Jones RL, Smith IE. Jones RL, et al. Among authors: smith ie. Expert Opin Drug Saf. 2004 Jul;3(4):317-27. doi: 10.1517/14740338.3.4.317. Expert Opin Drug Saf. 2004. PMID: 15268649 Review.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists. Dowsett M, et al. Among authors: smith ie. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s. Clin Cancer Res. 2005. PMID: 15701892 Clinical Trial.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Dowsett M, et al. Among authors: smith ie. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767642 Clinical Trial.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Smith IE, et al. J Clin Oncol. 2005 Aug 1;23(22):5108-16. doi: 10.1200/JCO.2005.04.005. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998903 Clinical Trial.
Proliferation marker Ki-67 in early breast cancer.
Urruticoechea A, Smith IE, Dowsett M. Urruticoechea A, et al. Among authors: smith ie. J Clin Oncol. 2005 Oct 1;23(28):7212-20. doi: 10.1200/JCO.2005.07.501. J Clin Oncol. 2005. PMID: 16192605 Review.
517 results